BioLineRx Ltd. (BLRX)
0.12
-0.02 (-12.66%)
At close: Jan 14, 2025, 3:59 PM
0.12
-2.60%
Pre-market Jan 15, 2025, 07:41 AM EST
undefined% (undefined)
| Bid | 0.12 |
| Market Cap | 17.54M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.29 |
| PE Ratio (ttm) | -0.42 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.12 |
| Volume | 10,810,334 |
| Avg. Volume (20D) | 4,485,939 |
| Open | 0.13 |
| Previous Close | 0.14 |
| Day's Range | 0.12 - 0.13 |
| 52-Week Range | 0.12 - 1.44 |
| Beta | undefined |
About BLRX
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in pat...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 27, 2011
Employees 79
Stock Exchange NASDAQ
Ticker Symbol BLRX
Website https://www.biolinerx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for BLRX stock is "Buy." The 12-month stock price forecast is $5.5, which is an increase of 4364.29% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
BioLineRx Ltd. is scheduled to release its earnings on Mar 25, 2025,
before market opens.
Analysts project revenue of $7.72M, reflecting a 60.83% YoY growth and earnings per share of 0, making a -100.00% decrease YoY.
Analysts project revenue of $7.72M, reflecting a 60.83% YoY growth and earnings per share of 0, making a -100.00% decrease YoY.
1 week ago ·
Source
-40.87%
BioLineRx shares are trading lower after the compa...
Unlock content with
Pro Subscription
5 months ago ·
Source
-12.48%
BioLineRx shares are trading lower. The company reported Q2 financial results.
